Heterogeneity of d‐glucuronyl C5‐epimerase expression and epigenetic regulation in prostate cancer

Cancer Medicine

Tatiana Y. Prudnikova³  Nikolaos Soulitzis⁴  Olesya S. Kutsenko³  Lyudmila A. Mostovich³  Klas Haraldson²  Ingemar Ernberg²  Vladimir I. Kashuba¹  Demetrios A. Spandidos⁴  Eugene R. Zabarovsky² 

[1] Institute of Molecular Biology and Genetics, Kiev, Ukraine;MTC, Karolinska Institute, Stockholm, Sweden;Institute of Molecular Biology and Biophysics SD RAMS, Novosibirsk, Russia;Medical School of University of Crete, Heraklion, Greece

关键词: d‐Glucuronyl C5‐epimerase;    expression;    heparansulfate proteoglycan;    heterogeneity;    methylation;    prostate cancer;   

DOI  :  10.1002/cam4.108

来源: Wiley

【 摘 要 】

Abstract

Heparansulfate proteoglycans (HSPG) play an important role in cell–cell and cell–matrix interactions and signaling, and one of the key enzymes in heparansulfate biosynthesis is d-glucuronyl C5-epimerase (GLCE). A tumor suppressor function has been demonstrated for GLCE in breast and lung carcinogenesis; however, no data are available as to the expression and regulation of the gene in prostate cancer. In this study, decreased GLCE expression was observed in 10% of benign prostate hyperplasia (BPH) tissues and 53% of prostate tumors, and increased GLCE mRNA levels were detected in 49% of BPH tissues and 21% of tumors. Statistical analysis showed a positive correlation between increased GLCE expression and Gleason score, TNM staging, and prostate-specific antigen (PSA) level in the prostate tumors (Pearson correlation coefficients GLCE/Gleason = 0.56, P < 0.05; GLCE/TNM = 0.62, P < 0.05; and GLCE/PSA = 0.88, P < 0.01), suggesting GLCE as a candidate molecular marker for advanced prostate cancer. Immunohistochemical analysis revealed an intratumoral heterogeneity of GLCE protein levels both in BPH and prostate cancer cells, resulting in a mixed population of GLCE-expressing and nonexpressing epithelial cells in vivo. A model experiment on normal (PNT2) and prostate cancer (LNCaP, PC3, DU145) cell lines in vitro showed a 1.5- to 2.5-fold difference in GLCE expression levels between the cancer cell lines and an overall decrease in GLCE expression in cancer cells. Methyl-specific polymerase chain reaction (PCR), bisulfite sequencing, and deoxy-azacytidin (aza-dC) treatment identified differential GLCE promoter methylation (LNCaP 70–72%, PC3 32–35%, DU145, and PNT2 no methylation), which seems to contribute to heterogeneous GLCE expression in prostate tumors. The obtained results reveal the complex deregulation of GLCE expression in prostatic diseases compared with normal prostate tissue and suggest that GLCE may be used as a potential model to study the functional role of intratumor cell heterogeneity in prostate cancer progression.

【 授权许可】

CC BY   
© 2013 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.